破解小细胞肺癌免疫治疗耐药:分子机制与新兴解决方案
本综述聚焦小细胞肺癌(SCLC)免疫检查点抑制剂(ICI)疗效有限的问题,系统梳理肿瘤内在免疫逃逸机制、免疫抑制性微环境及分子亚型分类,并汇总旨在恢复免疫应答的临床试验与转化策略,提出生物标志物引导和亚型分层的精准免疫治疗路线图。
要点
- SCLC中ICI仅带来中位生存期2-3个月改善,与高肿瘤突变负荷形成 paradox。
- 耐药涉及肿瘤内在机制(MHC I类下调、表观遗传抑制)与免疫抑制微环境。
- 分子亚型分类揭示不同免疫原性景观,可能预测免疫治疗反应。
核心结论
- SCLC免疫治疗耐药是多因素、复杂的,需生物标志物引导和亚型分层的精准免疫治疗策略。
研究设计与样本
- 综述文章,系统回顾SCLC免疫治疗耐药机制、分子亚型分类及恢复免疫应答的临床试验与转化策略。
主要发现
- ICI在SCLC中仅使中位生存期改善2-3个月,尽管SCLC具有高肿瘤突变负荷。
- 肿瘤内在免疫逃逸机制包括遗传驱动因素、MHC I类下调及表观遗传抑制。
- SCLC分子亚型分类揭示不同免疫原性景观,对免疫治疗反应有潜在预测价值。
- 正在开展或近期报道的临床试验涵盖联合ICI方案、表观遗传调节剂、抗原呈递通路激动剂及双特异性T细胞衔接器。
临床怎么用
- 临床应关注SCLC分子亚型及生物标志物,以指导免疫治疗的患者选择和试验设计。
- 可探索联合表观遗传调节剂、抗原呈递通路激动剂或双特异性T细胞衔接器等策略克服耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy with dismal prognosis. Although immune checkpoint inhibitors (ICIs) have revolutionized non-small cell lung cancer, their impact in SCLC has been modest, with only 2-3 months' improvement in median survival. This paradox persists despite SCLC's high tumor mutational burden, suggesting complex, multifactorial resistance mechanisms. Here we critically review the latest advances in understanding immunotherapy resistance in SCLC. We highlight tumor-intrinsic immune escape mechanisms, including genetic drivers, MHC class I downregulation, and epigenetic repression, as well as the profoundly immunosuppressive tumor microenvironment. We also examine the evolving classification of SCLC into molecular subtypes, which reveals distinct immunogenic landscapes with potential predictive value for immunotherapy response. Importantly, we integrate a comprehensive update on ongoing and recently reported clinical trials that aim to restore immune responsiveness, ranging from combination ICI regimens to novel strategies involving epigenetic modulators, antigen presenting pathway agonists, and bispecific T-cell engagers. Finally, we discuss translational strategies to overcome immunotherapy resistance and outline a precision immunotherapy roadmap, arguing for biomarker-guided and subtype-stratified clinical trial design. By synthesizing mechanistic, translational, and clinical perspectives, this review provides a framework for rational therapeutic innovation in SCLC.
引用
- Papavassiliou KA, Stravopodis DJ, Gogou VA, et al. Cracking the code of immunotherapy resistance in small cell lung cancer: molecular insights and emerging solutions. Am J Respir Crit Care Med. 2026. PMID: 41738120. doi:10.1093/ajrccm/aamaf124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。